This European approach to insulin management is now being introduced in Australia
Since the publication of the Diabetes Control and Complications Trial (DCCT) in 1993,1 improved glycaemic control in type 1 diabetes has been acknowledged as a desirable goal in theory, but frustratingly difficult to achieve in practice. Although bodies such as the American Diabetes Association recommend a glycated haemoglobin (HbA1c) target of < 7%,2 only around 20% of adults with type 1 diabetes under specialist supervision in Australian centres achieve this goal (data from the Australian National Diabetes Information Audit and Benchmarking Survey; Associate Professor Jeff Flack, Director, Diabetes Centre, Bankstown–Lidcombe Hospital, NSW, personal communication).
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
I am Director of the Queensland Diabetes Centre, which runs regular DAFNE courses, and President of the DAFNE Association of Australia, a not-for-profit association which promotes and disseminates the DAFNE method and has received funding from Novo Nordisk (Australia) and Abbott Australasia. I have also received speaker fees and assistance in attending meetings from Novo Nordisk and Eli Lilly Australia, manufacturers of insulin products.